Laboratory changes and prognostic indicators of the adverse course of chronic heart failure with preserved left ventricular ejection fraction, excess weight and concomitant atrial fibrillation
DOI:
https://doi.org/10.14739/2310-1237.2022.3.268186Keywords:
laboratory changes, prognosis, chronic heart failure, preserved ejection fraction, overweight, adiposity, atrial fibrillationAbstract
Aim. To investigate the peculiarities of clinical and laboratory changes and to identify prognostic indicators of the adverse course of chronic heart failure with preserved left ventricular ejection fraction (CHFprEF), excess weight and concomitant atrial fibrillation (AF).
Materials and methods. The open, prospective, cohort study in parallel groups included 248 patients with CHFprEF, overweight and abdominal obesity, average age 65.0 ± 11.0 years; 146 (58.9 %) women and 102 (41.1 %) men. The first group included 181 patients with CHFprEF and excess weight without concomitant AF, and the second group – 67 CHFprEF patients with excess weight and AF. The complex clinical examination was performed according to the standards, including complaints, medical and family history, clinical, laboratory and instrumental examinations.
Results. It has been established that patients with CHFprEF and overweight or abdominal obesity concomitant AF have a predisposition to anemia, which was manifested by significant lower indicators of hemoglobin and erythrocytes in parallel with lower values of lymphocytes, more pronounced signs of systemic inflammation, dysfunction of the kidneys and liver with manifestations of cholestasis, which indicated deeper functional and structural disorders of organs and systems. ROC-analysis of the patients with CHFprEF, excess weight and concomitant AF demonstrated increase in the clinical endpoints rate for patients with BMI ˃32 kg/m2, the waist circumference / hips circumference ratio ˃1.1 U, leucocytes level ˃6 × 109 l, serum creatinine ˃96 mcmol/l, urea ˃7.3 mmol/l, glomerular filtration rate ≤65 ml/min/1.73 m2, LDL / HDL cholesterol ratio ˃2.05 U. The 5-years death predictors were found in patients with CHFprEF, excess weight and concomitant AF: functional class of CHF ˃ІІ, HDL cholesterol ≤0.9 mmol/l, LDL cholesterol ≤0.66 mmol/l and triglycerides ≤1.45 mmol/l; additionally, there were defined the predictors of recurrent admission to hospital with the CHFprEF decompensation: leucocytes level ˃6 × 109 l, LDL cholesterol ˃2.49 mmol/l, the LDL / HDL cholesterol ratio ˃2.05 U and the atherogenic ratio ˃2.91 U.
Conclusions. In patients with CHFprEF and excess weight, concomitant AF was associated with more severe laboratory changes, which reflected deeper functional and structural disorders of organs and systems. Laboratory predictors of the adverse course of CHFprEF in this category of patients have been established.
References
Thygesen, L. C., Zinckernagel, L., Dalal, H., Egstrup, K., Glümer, C., Grønbæk, M., Holmberg, T., Køber, L., la Cour, K., Nakano, A., Nielsen, C. V., Sibilitz, K. L., Tolstrup, J. S., Zwisler, A. D., & Taylor, R. S. (2022). Cardiac rehabilitation for patients with heart failure: association with readmission and mortality risk. European heart journal. Quality of care & clinical outcomes, 8(8), 830-839. https://doi.org/10.1093/ehjqcco/qcab086
Rucker, D., & Joseph, J. (2022). Defining the Phenotypes for Heart Failure With Preserved Ejection Fraction. Current heart failure reports, 19(6), 445-457. https://doi.org/10.1007/s11897-022-00582-x
Borlaug B. A. (2020). Evaluation and management of heart failure with preserved ejection fraction. Nature reviews. Cardiology, 17(9), 559-573. https://doi.org/10.1038/s41569-020-0363-2
Ma, C., Luo, H., Fan, L., Liu, X., & Gao, C. (2020). Heart failure with preserved ejection fraction: an update on pathophysiology, diagnosis, treatment, and prognosis. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 53(7), e9646. https://doi.org/10.1590/1414-431X20209646
Del Buono, M. G., Iannaccone, G., Scacciavillani, R., Carbone, S., Camilli, M., Niccoli, G., Borlaug, B. A., Lavie, C. J., Arena, R., Crea, F., & Abbate, A. (2020). Heart failure with preserved ejection fraction diagnosis and treatment: An updated review of the evidence. Progress in cardiovascular diseases, 63(5), 570-584. https://doi.org/10.1016/j.pcad.2020.04.011
Yamashina, A., Nishikori, M., Fujimito, H., & Oba, K. (2022). Identification of predictive factors interacting with heart rate reduction for potential beneficial clinical outcomes in chronic heart failure: A systematic literature review and meta-analysis. International journal of cardiology. Heart & vasculature, 43, 101141. https://doi.org/10.1016/j.ijcha.2022.101141
Truby, L. K., & Rogers, J. G. (2020). Advanced Heart Failure: Epidemiology, Diagnosis, and Therapeutic Approaches. JACC. Heart failure, 8(7), 523-536. https://doi.org/10.1016/j.jchf.2020.01.014
Sciomer, S., Moscucci, F., Salvioni, E., Marchese, G., Bussotti, M., Corrà, U., & Piepoli, M. F. (2020). Role of gender, age and BMI in prognosis of heart failure. European journal of preventive cardiology, 27(2_suppl), 46-51. https://doi.org/10.1177/2047487320961980
Elagizi, A., Carbone, S., Lavie, C. J., Mehra, M. R., & Ventura, H. O. (2020). Implications of obesity across the heart failure continuum. Progress in cardiovascular diseases, 63(5), 561-569. https://doi.org/10.1016/j.pcad.2020.09.005
Reddy, Y., Obokata, M., Verbrugge, F. H., Lin, G., & Borlaug, B. A. (2020). Atrial Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation. Journal of the American College of Cardiology, 76(9), 1051-1064. https://doi.org/10.1016/j.jacc.2020.07.009
Taniguchi, N., Miyasaka, Y., Suwa, Y., Harada, S., Nakai, E., & Shiojima, I. (2020). Heart Failure in Atrial Fibrillation - An Update on Clinical and Echocardiographic Implications. Circulation journal, 84(8), 1212-1217. https://doi.org/10.1253/circj.CJ-20-0258
Mykhailovskyi, Ya. M. (2022). Vplyv klinichnykh i henetychnykh chynnykiv na stabilnist antykoahuliatsii varfarynom u khvorykh iz fibryliatsiieiu peredserd [The influence of clinical and genetic factors on the stability of warfarin’s anticoagulant effect in patients with atrial fibrillation]. Pathologia, 19(1), 12-17. [in Ukrainian]. https://doi.org/10.14739/2310-1237.2022.1.252662
Kolesnyk, M. Y., Mykhailovskyi, Y. M. (2021). The interrelation of CYP2C9, CYP4F2, VKORC1 genes polymorphisms with warfarin dose and hemorrhagic complications risk rise in patients with atrial fibrillation: a retrospective study. East European scienetific journal, 1(1), 37-43.
Kolesnyk, M. Yu., Kamyshnyi, О. М., & Mykhailovskyi, Ya. M. (2018). Vzaiemozviazok polimorfizmu heniv CYP2C9, CYP4F2, VKORC1 z rozvytkom hemorahichnykh uskladnen pry terapii varfarynom u khvorykh z fibryliatsiieiu peredserd: rezultaty odnotsentrovoho richnoho sposterezhennia [The interrelation of CYP2C9, CYP4F2, VKORC1 genes polymorphism and hemorrhagic complications of warfarin therapy in patients with atrial fibrillation: a single-center one-year study]. Ukrainskyi kardiolohichnyi zhurnal, (1), 54-59. [in Ukrainian].
Freedman, B., Hindricks, G., Banerjee, A., Baranchuk, A., Ching, C. K., Du, X., Fitzsimons, D., Healey, J. S., Ikeda, T., Lobban, T. C. A., Mbakwem, A., Narasimhan, C., Neubeck, L., Noseworthy, P., Philbin, D. M., Jr, Pinto, F. J., Rwebembera, J., Schnabel, R. B., Svendsen, J. H., Aguinaga, L., … Stepinska, J. (2021). World Heart Federation Roadmap on Atrial Fibrillation - A 2020 Update. Global heart, 16(1), 41. https://doi.org/10.5334/gh.1023
Ahn, M. S., Yoo, B. S., Yoon, J., Lee, S. H., Kim, J. Y., Ahn, S. G., Youn, Y. J., Lee, J. W., Son, J. W., Kim, H. S., Kang, D. R., Cho, H. J., Lee, H. Y., Jeon, E. S., Kang, S. M., Choi, D. J., & Cho, M. C. (2020). Guideline-directed therapy at discharge in patients with heart failure and atrial fibrillation. Heart (British Cardiac Society), 106(4), 292-298. https://doi.org/10.1136/heartjnl-2019-315240
Bavishi, A., & Patel, R. B. (2020). Addressing Comorbidities in Heart Failure: Hypertension, Atrial Fibrillation, and Diabetes. Heart failure clinics, 16(4), 441-456. https://doi.org/10.1016/j.hfc.2020.06.005
Ishigami, J., Grams, M. E., Naik, R. P., Caughey, M. C., Loehr, L. R., Uchida, S., Coresh, J., & Matsushita, K. (2018). Hemoglobin, Albuminuria, and Kidney Function in Cardiovascular Risk: The ARIC (Atherosclerosis Risk in Communities) Study. Journal of the American Heart Association, 7(2), e007209. https://doi.org/10.1161/JAHA.117.007209
McGranaghan, P., Saxena, A., Düngen, H. D., Rubens, M., Appunni,S., Salami, J., Veledar, E., Lacour, P., Blaschke, F., Obradovic, D., Loncar, G., Tahirovic, E., Edelmann, F., Pieske, B., & Trippel, T. D. (2021). Performance of a cardiac lipid panel compared to four prognostic scores in chronic heart failure. Scientific reports, 11(1), 8164. https://doi.org/10.1038/s41598-021-87776-w
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J., Coats, A., Falk, V., González-Juanatey, J. R., Harjola, V. P., Jankowska, E. A., Jessup, M., Linde, C., Nihoyannopoulos, P., Parissis, J. T., Pieske, B., Riley, J. P., Rosano, G., Ruilope, L. M., Ruschitzka, F., Rutten, F. H., … ESC Scientific Document Group (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European heart journal, 37(27), 2129-2200. https://doi.org/10.1093/eurheartj/ehw128
Voronkov, L. H., Amosova, K. M., Dziak, H. V., Zharinov, O. Y., Kovalenko, V. M., Korkushko, O. V., Nesukai, O. H., Sychov, O. S., Rudyk, Yu. S., & Parkhomenko, O. M. (2017). Rekomendatsii Asotsiatsii kardiolohiv Ukrainy z diahnostyky ta likuvannia khronichnoi sertsevoi nedostatnosti (2017) [Guidelines of the Ukrainian Association of Cardiology for the Diagnosis and Treatment of Chronic Heart Failure (2017)]. Sertseva nedostatnist ta komorbidni stany, (1, Suppl_1), 1-66. [in Ukrainian].
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström-Lundqvist, C., Boriani, G., Castella, M., Dan, G. A., Dilaveris, P. E., Fauchier, L., Filippatos, G., Kalman, J. M., La Meir, M., Lane, D. A., Lebeau, J. P., Lettino, M., Lip, G., Pinto, F. J., Thomas, G. N., ESC Scientific Document Group (2021). 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European heart journal, 42(5), 373-498. https://doi.org/10.1093/eurheartj/ehaa612
Cunha, F. M., Pereira, J., Ribeiro, A., Silva, S., Araújo, J. P., Leite-Moreira, A., Bettencourt, P., & Lourenço, P. (2019). The cholesterol paradox may be attenuated in heart failure patients with diabetes. Minerva medica, 110(6), 507-514. https://doi.org/10.23736/S0026-4806.19.06067-1
Bidzilya P. P., Kadzharian V. H., Kapshytar N. I. (2021). Klinichnyi perebih i naslidky khronichnoi sertsevoi nedostatnosti zi zberezhenoiu fraktsiieiu livoho shlunochka na tli nadlyshkovoi masy tila ta ozhyrinnia z suputnoiu fibryliatsiieiu peredserd [Clinical course and outcomes of chronic heart failure with preserved left ventricular ejection fraction in concomitant overweight and obesity with comorbid atrial fibrillation]. Zaporozhye medical journal, 23(6), 778-783. [in Ukrainian]. https://doi.org/10.14739/2310-1210.2021.6.236247
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
